Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Immunomodulators are chemicals that can aid immune function by altering the immune system's response to a threat, usually in a favorable way. Immunomodulators may be used alone or in combination with other drugs (such as a corticosteroid) to treat nonresponse or intolerance to aminosalicylates, antibiotics, or corticosteroids, to prevent recurrence after surgery, to bolster or optimize the effect of a biologic drug, and to prevent the development of biologic drug resistance, among other things. By product type, they are segmented into immunosuppressants and immunostimulants. Immunosuppressants suppress the immune response in organ transplantation and autoimmune illnesses, whereas immunostimulants boost the immune response in infections, immunodeficiency (such as AIDS), and malignancies.
The global immunomodulators market is estimated to be valued at US$ 91850.0 Million in 2021 and is expected to reach US$ 156378.2 million by 2028, at a CAGR of 7.9% during the forecast period (2021–2028).
Figure 1. Global Immunomodulators Market Share (%), By Region, 2021
Rising prevalence of multiple sclerosis is expected to drive the market growth over the forecast period.
Multiple sclerosis (MS) is the second leading cause of death, after cardiovascular diseases. Rising prevalence of multiple sclerosis is expected to drive the market growth over the forecast period. For instance, according to a report published in the Multiple Sclerosis Journal 2020, MS affected an estimated 2.8 million people around the world (35.9 per 100,000 population). Since 2013, despite the fact that MS has become more common in every part of the world, there are still disparities in prevalence estimates. The average age of diagnosis is 32 years, and the pooled incidence rate across 75 reporting nations is 2.1 per 100,000 people each year. MS affects twice as many women as it does men.
Immunomodulators Market Report Coverage
||Market Size in 2021:
||US$ 91850.0 Mn
|Historical Data for:
||2017 to 2020
||2021 to 2028
|Forecast Period 2021 to 2028 CAGR:
||2028 Value Projection:
||US$ 156378.2 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Product Type: Immunosuppressants (Calcineurin Inhibitors, Glucocorticoids, Antimetabolites, Others), Immunostimulants (Vaccines, Antibodies, Others)
- By Application: Oncology, Respiratory, HIV, Others
- By End User: Hospitals, Clinics, Others
F. Hoffmann-La Roche Ltd., Biogen Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Amgen, Inc., Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., Eli Lilly and Company, Abbott Laboratories, Johnson & Johnson, and Pfizer Inc.
- Rising prevalence of multiple sclerosis
- Increasing prevalence of autoimmune disorders
- Rising availability of drugs
- Rising number of ongoing clinical trials for the development of immunotherapeutic agents
|Restraints & Challenges:
- Side effects associated with immunomodulating drugs
- Strict regulations with respect to clinical studies by regulatory bodies
Figure 2. Global Immunomodulators Market Share, By Application, 2021
Rising cases of rheumatoid arthritis is expected to boost the market growth.
The number of active clinical trials to develop immunotherapeutic drugs, such as laquinimod, ozanimod, and ponesimod, is expected to drive the global immunomodulators market in the forecast period. Apart from that, the growing need to treat autoimmune diseases such as rheumatoid arthritis is expected to drive demand for immunomodulators. For instance, in 2018, an estimated 400,000 people in the U.K. had rheumatoid arthritis, and an estimated four million people had an autoimmune disease, according to the British Society for Global Immunomodulators.
Global Immunomodulators Market– Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it as a public health emergency in 2020. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported globally as of August 2, 2021, are approximately 198,234,951 confirmed cases with around 4,227,359 deaths. The Coronavirus (COVID-19) outbreak started from Wuhan, China and has spread across continents, affecting various industries globally.
The COVID-19 pandemic is expected to have a favorable impact on the industry in the foreseeable future, owing to increased sales of immunomodulating products. Furthermore, in order to maintain sales, several key players strive to establish a balance between demand and supply. They're also attempting to increase their investments in quality control, refine their R&D efforts, and improve supply chain management.
Global Immunomodulators Market: Restraint
Side effects associated with immunomodulating drugs such as Thalidomide (Thalomid), lenalidomide (Revlimid), and pomalidomide (Pomalyst) include drowsiness, exhaustion, constipation, low blood cell counts, and neuropathy (painful nerve damage). There's also a higher chance of major blood clots formation (that start in the leg and can travel to the lungs). With thalidomide, this is more common than with the other medicines (lenalidomide and pomalidomide). Additionally, strict regulations with respect to clinical studies by regulatory bodies is hampering the market growth.
Major players operating in the global immunomodulators market include F. Hoffmann-La Roche Ltd., Biogen Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Amgen, Inc., Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., Eli Lilly and Company, Abbott Laboratories, Johnson & Johnson, and Pfizer Inc.